Divide and Conquer : Using Patient Stratification to Optimize Therapeutic Drug Development in Inflammatory Bowel Disease

Cite this article: Bilsborough J, McGovern DPB, Targan SR (2014) Divide and Conquer: Using Patient Stratification to Optimize Therapeutic Drug Development in Inflammatory Bowel Disease. J Immunol Clin Res 2(1): 1017. *Corresponding author Janine Bilsborough, F.Widjaja Inflammatory Bowel and Immunobiology Research Institute, CedarsSinai Medical Center, Los Angeles, CA, USA, Tel: 310 423 7797; Fax: 310 423 0224; E-mail:

[1]  Désirée van der Heijde,et al.  Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial , 2013, The Lancet.

[2]  Rob Knight,et al.  A Modular Organization of the Human Intestinal Mucosal Microbiota and Its Association with Inflammatory Bowel Disease , 2013, PloS one.

[3]  S. Targan,et al.  Multidimensional Prognostic Risk Assessment Identifies Association Between IL12B Variation and Surgery in Crohn’s Disease , 2013, Inflammatory bowel diseases.

[4]  Yusuke Nakamura,et al.  Association Study of 71 European Crohn's Disease Susceptibility Loci in a Japanese Population , 2013, Inflammatory bowel diseases.

[5]  J. Ortonne,et al.  Secukinumab induction and maintenance therapy in moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled, phase II regimen‐finding study , 2012, The British journal of dermatology.

[6]  Rashesh Shah,et al.  The promise and pitfalls of serologic testing in inflammatory bowel disease. , 2012, Gastroenterology clinics of North America.

[7]  Marc Vandemeulebroecke,et al.  Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial , 2012, Gut.

[8]  S. Kane,et al.  Drug development in inflammatory bowel disease: The role of the FDA , 2011, Inflammatory bowel diseases.

[9]  S. Danese.  New therapies for inflammatory bowel disease: from the bench to the bedside , 2011, Gut.

[10]  P. Higgins,et al.  The Prognostic Power of the NOD2 Genotype for Complicated Crohn's Disease: A Meta-Analysis , 2011, The American Journal of Gastroenterology.

[11]  R. Xavier,et al.  Virus-Plus-Susceptibility Gene Interaction Determines Crohn's Disease Gene Atg16L1 Phenotypes in Intestine , 2010, Cell.

[12]  G Van Assche,et al.  Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis , 2009, Gut.

[13]  P. Rutgeerts,et al.  Predictive Model for the Outcome of Infliximab Therapy in Crohn's Disease Based on Apoptotic Pharmacogenetic Index and Clinical Predictors , 2007, Inflammatory bowel diseases.

[14]  J. Satsangi,et al.  The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications , 2006, Gut.

[15]  S. Targan,et al.  Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.

[16]  S. Targan,et al.  Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. , 1996, Gastroenterology.

[17]  David C. Wilson,et al.  Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease , 2012, Nature.